Curiously, overall responses among wild-type FLT3 AML patients were reported for both gilteritinib (12% of composite overall responses) and quizartinib (30–36% of composite complete remissions) [9, 11]. The gene discussed is FLT3; the disease is acute myeloid leukemia.